11/28/2023 0 Comments Checkmate 9la publicationAs our understanding of cancer biology expanded during the 2000s–2010s, better drugs were added to our armamentarium with the introduction of targeted therapies for oncogene-addicted NSCLC and anti-VEGF drugs added to traditional chemotherapy. While these regimens improved survival, they did so at the cost of toxic side effects and long-term prognosis remained poor ( 2). Cytotoxic chemotherapy was the standard-and only-treatment for metastatic lung cancer until the mid-2000s, with numerous drugs and combinations trialed. While this remains a deadly disease, there has been a significant expansion of the number of treatment options available to patients with metastatic NSCLC (mNSCLC) over the last 10 years. Lung cancer is the second most common cancer in the United States and the leading cause of cancer death, with over 135,000 people expected to succumb by the end of 2020 ( 1). ![]() Email: 23 October 2020 Accepted: 16 November 2020 Published: 30 December 2020. Associate Professor of Internal Medicine (Medical Oncology), Yale School of Medicine/Yale Cancer Center, New Haven, CT, USA.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |